SAR439794 / Sanofi - LARVOL DELTA

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients (clinicaltrials.gov) - P1; N=44; Recruiting; Sponsor: Sanofi; Trial completion date: Jan 2020 ➔ May 2020

Trial completion date • Biosimilar • Immunology

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Sanofi; N=44 ➔ 27

Clinical • Enrollment change • Allergy • Food Hypersensitivity • Immunology

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients (clinicaltrials.gov) - P1; N=44; Completed; Sponsor: Sanofi; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients (clinicaltrials.gov) - P1; N=44; Active, not recruiting; Sponsor: Sanofi; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed